Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds

References

• Bommer C, Sagalova V, Heesemann E, et al. Global Economic Burden of Diabetes in Adults: projections From 2015 to 2030. Diabetes Care. 2018;41(5):963–970.
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. ‘Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019; 157:107843.
   PubMed Web of Science ®Google Scholar
• Castaneda-Sceppa C, Castaneda F. Sodium-dependent glucose transporter protein as a potential therapeutic target for improving glycemic control in diabetes. Nutr Rev. 2011;69(12):720–729.
   PubMed Web of Science ®Google Scholar
• Tsushima Y, Lansang MC, Makin V. The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleve Clin J Med. 2021;88(1):47–58.
   PubMed Web of Science ®Google Scholar
• Fisher M, McKay G. Essentials of SGLT2 Inhibitors in Diabetes. Springer International Publishing Switzerland; 2017. 13–35. Doi:10.1007/978-3-319-43296-0
   Google Scholar
• Boeder S, Edelman SV. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: a review of randomized controlled trials. Diabetes Obesity Metab. 2019;21(S2):62–77.
   PubMedGoogle Scholar
• Chao EC, Henry RR. SGLT2 inhibition-A novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559.
   PubMed Web of Science ®Google Scholar
• Fattah H, Vallon V. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. Drugs. 2018;78(7):717–726.
   PubMed Web of Science ®Google Scholar
• Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079–2086.
   PubMed Web of Science ®Google Scholar
• Haider K, Pathak A, Rohilla A, et al. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: a review. Eur J Med Chem. 2019;184:111773.
   PubMed Web of Science ®Google Scholar
• Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48(9):1794–1800.
   PubMed Web of Science ®Google Scholar
• Choi CI. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents. Molecules. 2016;21(9):1–18.
   Web of Science ®Google Scholar
• Moradi-Marjaneh R, Paseban M, Sahebkar A. Natural products with SGLT2 inhibitory activity: possibilities of application for the treatment of diabetes. Phytother Res. 2019;33(10):2518–2530.
   PubMed Web of Science ®Google Scholar
• Dobbins RL, O’Connor-Semmes R, Kapur A, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obesity Metab. 2012;14(1):15–22.
   PubMed Web of Science ®Google Scholar
• Markham A. Remogliflozin Etabonate: first Global Approval. Drugs. 2019;79(10):1157–1161.
   PubMed Web of Science ®Google Scholar
• Dobbins R, Hussey KE, Connor-Semmes RO, Andrews S, et al. ‘Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin’. BMC Pharmacology and Toxicology. 2021; 22(1): 1–11. DOI:10.1186/s40360-021-00502-0
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Gause-Nilsson I, Xu J, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. J Diabetes Complications. 2017;31(7):1215–1221.
   PubMed Web of Science ®Google Scholar
• Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864–876.
   PubMed Web of Science ®Google Scholar
• Saleem F. Dapagliflozin: cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus. Cureus. 2017;9:10.
   Web of Science ®Google Scholar
• Dhillon S. Dapagliflozin: a Review in Type 2 Diabetes. Drugs. 2019;79(10):1135–1146.
   PubMed Web of Science ®Google Scholar
• Deeks ED, Scheen AJ. Canagliflozin: a Review in Type 2 Diabetes. Drugs. 2017;77(14):1577–1592.
   PubMed Web of Science ®Google Scholar
• Minami T, Kameda A, Terauchi Y. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opin Pharmacother. 2021;22(16):2087–2094.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Empagliflozin: a Review in Type 2 Diabetes. Drugs. 2018;78(10):1037–1048.
   PubMed Web of Science ®Google Scholar
• Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119–129.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(15):1769–1784.
   PubMed Web of Science ®Google Scholar
• Goldman JD. Combination of Empagliflozin and Metformin Therapy: a Consideration of its Place in Type 2 Diabetes Therapy. Clin Med Insights. 2018; 11. doi:10.1177/1179551418786258
   Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–225.
   PubMed Web of Science ®Google Scholar
• Marrs JC, Anderson SL. Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs Context. 2021;9:1–10.
   Google Scholar
• Markham A. Ertugliflozin: first Global Approval. Drugs. 2018;78(4):513–519.
   PubMed Web of Science ®Google Scholar
• Hu J, Deng A, Zhao Y. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2018;19(16):1841–1847.
   PubMed Web of Science ®Google Scholar
• Alkabbani W, Gamble JM. Profile of ipragliflozin, an oral sglt-2 inhibitor for the treatment of type 2 diabetes: the evidence to date. Drug Des Devel Ther. 2021;15:3057–3069.
   PubMed Web of Science ®Google Scholar
• Ohkura T. Ipragliflozin: a novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes. 2015;6(1):136.
   PubMed Web of Science ®Google Scholar
• Kadokura T, Zhang W, Krauwinkel W, et al. Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin. Clin Pharmacokinet. 2014;53(11):975–988.
   PubMed Web of Science ®Google Scholar
• Koshizaka M, Ishikawa K, Ishibashi R, et al. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: subanalysis of a prospective, randomized, controlled study (PRIME-V study). J Diabetes Investig. 2021;12(2):200–206.
   PubMed Web of Science ®Google Scholar
• Aharon-Hananel G, Raz I. An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opin Pharmacother. 2019;20(7):781–790.
   PubMed Web of Science ®Google Scholar
• Pafili K, Maltezos E, Papanas N. Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;12(11):1367–1380.
   PubMed Web of Science ®Google Scholar
• Yabe D, Hamamoto Y, Seino Y, et al. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. Expert Opin Drug Saf. 2017;16(10):1211–1218.
   PubMed Web of Science ®Google Scholar
• Yang J, Yang X, Wang C, et al. Sodium-glucose-linked transporter 2 inhibitors from Sophora flavescens. Med Chem Res. 2015;24(3):1265–1271.
   Web of Science ®Google Scholar
• Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15(18):2741–2749.
   PubMed Web of Science ®Google Scholar
• Samukawa Y, Sata M, Furihata K, et al. Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: a Pharmacokinetic Study. Clin Pharmacol Drug Dev. 2017;6(5):439–447.
   PubMed Web of Science ®Google Scholar
• Markham A, Keam SJ. Sotagliflozin: first Global Approval. Drugs. 2019;79(9):1023–1029.
   PubMed Web of Science ®Google Scholar
• Rendell MS. Efficacy and safety of sotagliflozin in treating diabetes type 1. Expert Opin Pharmacother. 2018;19(3):307–315.
   PubMed Web of Science ®Google Scholar
• Chatzopoulos G, Tziomalos K. An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes. Expert Opin Pharmacother. 2020;21(15):1799–1803.
   PubMed Web of Science ®Google Scholar
• Mohan V, Mithal A, Joshi SR, et al. Remogliflozin etabonate in the treatment of type 2 diabetes: design, development, and place in therapy. Drug Des Devel Ther. 2020;14:2487–2501.
   PubMed Web of Science ®Google Scholar
• Beitelshees AL, Leslie BR, Taylor SI. Sodium–glucose cotransporter 2 inhibitors: a case study in translational research. Diabetes. 2019;68(6):1109–1120.
   PubMed Web of Science ®Google Scholar
• Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–1729.
   PubMed Web of Science ®Google Scholar
• Kshirsagar RP, Kulkarni AA, Chouthe RS, et al. SGLT inhibitors as antidiabetic agents: a comprehensive review. RSC Adv. 2020;10(3):1733–1756.
   PubMed Web of Science ®Google Scholar
• Devineni D, Polidori D, Curtin C, et al. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. Clin Ther. 2016;38(1):89e1–98.e1.
   Web of Science ®Google Scholar
• Ohgaki R, Wei L, Yamada K, et al. Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics, sidedness of action, and transporter-associated incorporation accounting for its pharmacodynamic and pharmacokinetic featuress. J Pharmacol Exp Ther. 2016;358(1):94–102.
   PubMed Web of Science ®Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors A journal of Pharamacology and Therapeutics . 2012;14(1):83–90 doi:10.1111/j.1463-1326.2011.01517.x.
   Google Scholar
• Fediuk DJ, Nucci G, Dawra VK, et al. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clin Pharmacokinet. 2020;59(8):949–965.
   PubMed Web of Science ®Google Scholar
• Tahara A, Kurosaki E, Yokono M, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg’s Arch Pharmacol. 2012;385(4):423–436.
   Google Scholar
• Faillie JL. Pharmacological aspects of the safety of gliflozins. Pharmacol Res. 2017;118:71–81.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Takano Y, Schwab D, et al. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus. Drug Res (Stuttg). 2019;69(6):314–322.
   PubMed Web of Science ®Google Scholar
• Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs. 2014;74(8):939–944.
   PubMed Web of Science ®Google Scholar
• Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs. 2014;74(8):945–950.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with lx4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015;38(3):431–438.
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a Randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92(2):158–169.
   PubMed Web of Science ®Google Scholar
• He X, Fang J, Huang L, et al. Sophora flavescens Ait.: traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol. 2015;172:10–29.
   PubMed Web of Science ®Google Scholar
• Li JJ, Zhang X, Shen X-C, et al. Phytochemistry and biological properties of isoprenoid flavonoids from Sophora flavescens Ait. Fitoterapia. 2020;143:104556.
   PubMed Web of Science ®Google Scholar
• Sato S, Takeo J, Aoyama C, et al. Na+-Glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007;15(10):3445–3449.
   PubMed Web of Science ®Google Scholar
• Morikawa T, Tao J, Toguchida I, et al. Structures of New Cyclic Diarylheptanoids and Inhibitors of Nitric Oxide Production from Japanese Folk Medicine Acer n ikoense. J Nat Prod. 2003;66(1):86–91.
   PubMed Web of Science ®Google Scholar
• Kurimoto SI, Sasaki YF, Suyama Y, et al. Acylated Triterpene Saponins from the Stem Bark of Acer nikoense (Aceraceae). Chem Pharm Bull. 2016;64(7):924–929.
   PubMed Web of Science ®Google Scholar
• Shimokawa Y, Akao Y, Hirasawa Y, et al. Gneyulins A and B, Stilbene Trimers, and Noidesols A and B, Dihydroflavonol- C -Glucosides, from the Bark of Gnetum gnemonoides. J Nat Prod. 2010;73(4):763–767.
   PubMed Web of Science ®Google Scholar
• Khyade MS, Kasote DM, Vaikos NP. Alstonia scholaris (L.) R. Br. and Alstonia macrophylla Wall. ex G. Don: a comparative review on traditional uses, phytochemistry and pharmacology. J Ethnopharmacol. 2014;153(1):1–18.
   PubMed Web of Science ®Google Scholar
• Changwichit K, Khorana N, Suwanborirux K, et al. Bisindole alkaloids and secoiridoids from Alstonia macrophylla Wall. ex G. Don. Fitoterapia. 2011;82(6):798–804.
   PubMed Web of Science ®Google Scholar
• Arai H, Hirasawa Y, Rahman A, et al. Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010;18(6):2152–2158.
   PubMed Web of Science ®Google Scholar
• Iliya I, Tanaka T, Iinuma M, et al. Stilbene derivatives from two species of Gnetaceae. Chem Pharm Bull. 2002;50(6):796–801.
   PubMed Web of Science ®Google Scholar
• Chan SW. Panax ginsengRhodiola rosea and Schisandra chinensis. Int J Food Sci Nutr. 2012;63(SUPPL.1):75–81.
   PubMed Web of Science ®Google Scholar
• Zhang M, Xu L, Yang H. Schisandra chinensis fructus and its active ingredients as promising resources for the treatment of neurological diseases. Int J Mol Sci. 2018;19(7). DOI:10.3390/ijms19071970
   Web of Science ®Google Scholar
• Qu Y, Chan JY-W, Wong C-W, et al. Antidiabetic Effect of Schisandrae Chinensis Fructus Involves Inhibition of the Sodium Glucose Cotransporter. Drug Dev Res. 2015;76(1):1–8.
   PubMed Web of Science ®Google Scholar
• Morita H, Deguchi J, Motegi Y, et al. Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorganic Med Chem Lett. 2010;20(3):1070–1074.
   PubMed Web of Science ®Google Scholar
• Choi MK, Nam SJ, Ji H-Y, et al. Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with dapagliflozin and ipragliflozin. Pharmaceutics. 2020;12(3):1–16.
   Web of Science ®Google Scholar
• Azzam O, Carnagarin R, Lugo-Gavidia LM, et al. Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opin Pharmacother. 2021;22(16):2095–2103.
   PubMed Web of Science ®Google Scholar
• Weng J, Zeng L, Zhang Y, et al. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obesity Metab. 2021;23(8):1754–1764.
   PubMed Web of Science ®Google Scholar